Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced that the Court of Chancery of the State of Delaware has issued an order granting final approval of a …
Hemispherx BioPharma, Inc (NYSE:HEB) that it has entered into definitive agreements with two healthcare focused institutional investors for an offering of shares of common …
Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced that it has received approval of its New Drug Application (NDA) from Administracion Nacional de Medicamentos, Alimentos y …
Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced that the first order of rintatolimod (Ampligen®) for the Early Access Program (EAP) in Europe has been shipped with …
Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced that it has entered into a Clinical Trial, Sales, Marketing, Distribution, and Supply Agreement with Scientific Products Pharmaceutical Co. …
Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced a Voluntary Pay for Stock Plan (the “Plan”). Hemispherx Biopharma is seeking to create ownership incentives as well as …
Hemispherx BioPharma, Inc (NYSE:HEB) announced its financial results for the nine months ended September 30, 2015. The net loss (including non-cash effects) was approximately …
Hemispherx BioPharma, Inc (NYSEMKT:HEB) announces that the European subsidiary, “Hemispherx Biopharma Europe N.V.
Hemispherx BioPharma, Inc (NYSE MKT:HEB) recently hosted a Stockholder Open House in their manufacturing and Research and Development (R&D) facility in New Brunswick, …
Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced last week in its Quarterly Report on Form 10-Q that it has encountered delays associated with the supply of …
